Deepak Madhavan
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $162,945 of the $189,072 with a category attached, or 86.2%. Neuropace, Inc. accounts for 84.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $120,074 and has fallen 90.7% since, to $11,108 in 2024. Among neurology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $2148.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$160K
- Greenwich Biosciences, Inc.$22K
- Livanova USA, Inc.$6K
- Siemens Medical Solutions USA, Inc.$64
- Neurelis, Inc.$42
- Supernus Pharmaceuticals, Inc.$36
- plus $48 from 3 others
Across 6 payments — averaging $5769.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$33K
- Neuropace, Inc.$1K
What the payments were for
- Consulting fees$162,94586%
- Speaking & faculty fees$23,51912%
- Travel & lodging$8330%
- Food & beverage$1,7741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 45 | $160,162 |
| Greenwich Biosciences, Inc. | 26 | $22,364 |
| Livanova USA, Inc. | 9 | $6,355 |
| Siemens Medical Solutions USA, Inc. | 2 | $64 |
| Neurelis, Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 1 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$155,323
- Epidiolex$22,018
- VNS Therapy$4,250
- RNS System$4,170
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$2,008
How this compares
$189,072 in reported general payments places this provider in the 95th percentile of 105 neurology providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 13 | $93,283 |
| Lamictal XrLamotrigine | 28 | $80,303 |
| Keppra XrLevetiracetam | 13 | $28,526 |
| Lamotrigine ErLamotrigine | 11 | $1,545 |
Paid to pharmacies, not to this prescriber.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
- Abhishek SinghOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.